Watch AVAI. Know when insiders buy.
One email the day a filing lands. Free.
AVAI
AVAI BIO, INC.
0.10
−0.00 −1.94%
USD · close Oct 22
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $15.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$1.8MNET CASH $54K52W 0.10 – 0.78SEC XBRL · TTM TO Invalid Date
How AVAI rewrote its risk factors
Text kept
89%
of sentences unchanged
Added
7
new sentences
Dropped
7
sentences removed
Length
+6
words, now 3,401
New in FY2026
- The Company does not accrue or capitalize development costs (or any costs to this effect) and expense it to its profit and loss statements as required by accounting principles generally accepted in the United States of America (“U.S.
- As such, the Company incurred a net loss of $1,749,509 for the year ended March 31, 2026 and net loss of $1,142,115 for the year ended March 31, 2025.
- The Company had a stockholders’ deficit of $2,815,155 and an accumulated deficit of $5,868,019 as of March 31, 2026.
- We expect that we have sufficient capital to maintain operations through the year of 2026/7.
- For example, for the years ended March 31, 2026 and 2025, we reported that our disclosure controls and procedures were not effective due to the lack of resources and the reliance on outside consultants.
- CYBERSECURITY OVERSIGHT GAPS We do not yet maintain a formal enterprise risk management program, and our board has not established a cybersecurity subcommittee.
- Of the 153,916,565 shares of our Common Stock outstanding as of the date of this Annual Report, approximately 38,562,563 are restricted and 115,354,002 shares are freely tradable without restriction pursuant to Rule 144.
Gone since FY2025
- The Company does not accrue or capitalize development costs (or any costs to this effect) and expense it to its profit and loss statements as required by US GAAP.
- As such, the Company incurred a net loss of $1,142,115 for the year ended March 31, 2025 and net loss of $2,128,475 for the year ended March 31, 2024.
- The Company had a stockholders’ deficit of $1,563,872 and an accumulated deficit of $4,118,510 as of March 31, 2025.
- We expect that we have sufficient capital to maintain operations through the year of 2025/6.
- For example, for the years ended March 31, 2025 and 2024, we reported that our disclosure controls and procedures were not effective due to the lack of resources and the reliance on outside consultants.
- TERMINATION OF WIRED4HEALTH APA CYBERSECURITY OVERSIGHT GAPS We do not yet maintain a formal enterprise risk management program, and our board has not established a cybersecurity subcommittee.
- Of the 137,511,233 shares of our Common Stock outstanding as of the date of this Annual Report, approximately 32,493,072 are restricted and 105,018,161 shares are freely tradable without restriction pursuant to Rule 144.
Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2025 ↗, FY2026 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.